LEO Pharma lures industry veteran to head global development

29 May 2018

Privately-held dermatology specialist LEO Pharma today announced that Dr Christian Antoni has been appointed as senior vice president for global development at the Danish firm as of June 1, 2018.

In this role, he will be globally responsible for all areas covering chemistry manufacturing and control, regulatory affairs, clinical operations, medical science and safety as well as project management.

Dr Antoni brings more than 20 year of experience in drug development from academia as well as the pharmaceutical industry to LEO Pharma. For the past 14 years, he has been building and heading global teams from the US at leading pharmaceutical companies such as Schering-Plough, Switzerland’s Novartis (NOVN: VX), and most recently, over the last four years at French drugmaker Sanofi (Euronext: SAN), where he has established and led the therapeutic area for immunology and inflammation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK